Kymera Therapeutics Inc
$ 71.29
-9.15%
02 Jun - close price
- Market Cap 6,454,753,000 USD
- Current Price $ 71.29
- High / Low $ 78.87 / 71.14
- Stock P/E N/A
- Book Value 19.42
- EPS -3.58
- Next Earning Report 2026-08-10
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -0.27 %
- 52 Week High 103.00
- 52 Week Low 36.65
About
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$118.27
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-26 | 2025-11-04 | 2025-08-11 | 2025-05-09 | 2025-02-27 | 2024-10-31 | 2024-08-07 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.71 | -0.97 | -0.94 | -0.95 | -0.82 | -0.89 | -0.82 | -0.58 | -0.62 | -0.25 | -0.9 | -0.67 |
| Estimated EPS | -0.86 | -0.79 | -0.78 | -0.8 | -0.91 | -0.7882 | -0.84 | -0.66 | -0.72 | -0.4 | -0.7 | -0.74 |
| Surprise | 0.15 | -0.18 | -0.16 | -0.15 | 0.09 | -0.1018 | 0.02 | 0.08 | 0.1 | 0.15 | -0.2 | 0.07 |
| Surprise Percentage | 17.4419% | -22.7848% | -20.5128% | -18.75% | 9.8901% | -12.9155% | 2.381% | 12.1212% | 13.8889% | 37.5% | -28.5714% | 9.4595% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-10 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.76 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KYMR
2026-05-30 12:39:54
Kymera Therapeutics (KYMR) is expected to see meaningful upside driven by clinical milestones in its immunology programs, particularly its oral STAT6 degrader KT-621, which analysts believe could act as an "oral Dupixent." Despite some cautious adjustments to revenue growth and profit margin assumptions by analysts, the company's strong pipeline, strategic partnerships, and solid cash runway into mid-2027 are viewed as key drivers for long-term growth and market leadership in protein degradation. However, high R&D expenses and reliance on partnerships pose risks to future profitability and market position.
2026-05-29 07:09:18
AJU IB Investment Co. Ltd. significantly reduced its stake in Kymera Therapeutics, Inc. by 95.7% in the fourth quarter, selling 437,411 shares. Despite this, other institutional investors have increased their positions. Kymera Therapeutics recently reported better-than-expected first-quarter results, and analysts maintain a "Moderate Buy" rating with an average price target of $118.10.
2026-05-28 17:40:14
Kymera Therapeutics presented Phase 1b biomarker data for its oral STAT6 degrader, KT-621, showing robust STAT6 degradation and broad Type 2 inflammation gene modulation for atopic dermatitis and asthma. These findings support KT-621's potential as an oral alternative to injectable biologics, reinforcing Kymera's investment narrative for oral protein degraders in large inflammatory diseases. While recent non-dilutive funding from Gilead helps extend cash resources, the company still faces significant R&D costs and reliance on future trial outcomes.
2026-05-28 10:44:02
Seven Grand Managers LLC has initiated a new position in Kymera Therapeutics (NASDAQ:KYMR), purchasing 30,000 shares valued at approximately $2.33 million in the fourth quarter. This move comes as several other institutional investors have adjusted their holdings in the biotechnology company, and despite recent insider sales by the director and CEO. Analysts currently give Kymera Therapeutics a "Moderate Buy" consensus rating with a target price of $118.10.
2026-05-27 22:11:05
Kymera Therapeutics' COO, Jeremy G. Chadwick, sold 17,184 shares of common stock in pre-planned, open-market transactions on May 26-27, 2026, at weighted-average prices ranging from $77.99 to $82.15 per share. These sales were automatically executed to cover tax withholding obligations related to restricted stock unit vesting and were conducted under a Rule 10b5-1 trading plan established in December 2025. Following these transactions, Chadwick directly holds 44,018 Kymera shares.
2026-05-27 21:40:02
Kymera Therapeutics COO, Jeremy G. Chadwick, sold 17,184 shares totaling approximately $1.37 million on May 26 and 27, 2026. These sales, including those for tax obligations and a pre-arranged trading plan, occurred as KYMR shares have seen a 190% return over the past year. Kymera also reported strong Q1 2026 financial results, exceeding revenue and EPS expectations, and shared positive clinical and preclinical data for its drug candidates.
